Abstract: Method of purifying a protein from a solution of substances comprising the steps of passing the solution through an ion exchange material at a pH which facilitates binding of the protein of interest, washing the bound protein at a different pH at which the bound protein does not elute but which the free protein would not bind to the ion exchange material, and then eluting the protein at a pH which facilitates elution. Method is especially useful in purification of antibodies such as antibodies to tumor necrosis factor.

Abstract: This invention relates to a method for treating or preventing anaerobe infections in humans and lower animals. This invention further relates to compositions and kits containing peroxy acids useful for treating or preventing anaerobe infections according to the method of the present invention.

Abstract: A modified biologically active protein consisting essentially of a biologically active protein bonded to lecithin via a covalent linking group and a pharmaceutical composition comprising the modified biologically active protein in a pharmaceutically-acceptable carrier. The biologically active proteins include antibodies, superoxide dismutase, insulin, and callidinogenase. Lecithin derivatives are also disclosed.

Abstract: The invention provides chemically modified proteins having a group of the formula: ##STR1## wherein R represents a hydrogen atom or a lower alkyl, m represents an optional positive integer and n represents an integer 1 to 4, the group being bonded to at least one primary amino group of the protein, and a method of producing the same. The chemically modified proteins according to the invention can be produced by reacting a protein with an imidoester of the formula: ##STR2## wherein R, n and m are as defined above, R' represents a group constituting an imidoester with an adjacent imidoyl group. The chemically modified proteins according to the invention are useful as drugs, among others.

Abstract: A broadly active viral inhibitor, termed UTI-.beta., is disclosed and having the following characteristics:(a) an apparent molecular mass of about 60 to about 90 kDa, based on HPLC size exclusion chromatography;(b) broad antiviral activity against a number of different viruses including herpesviruses, poxviruses, picornaviruses, paramyxoviruses, alphaviruses, flaviviruses and bunyaviruses;(c) lacking species specificity;(d) stable to temperatures ranging between 4.degree. C. and 80.degree. C., and denatured by treatment at 80.degree. C. for greater than 10 minutes;(e) unstable to periodate oxidation;(f) found spontaneously in mammalian host serum in the absence of viral infection;(g) both carbohydrate and protein structure; and(h) stable or enhanced viral inhibitory activity after proteolytic digestion.This viral inhibitor is useful for the treatment and prophylaxis of a broad range of viral infections occurring in mammalian hosts.

Abstract: There is disclosed an antibody and antibody-drug conjugate for targeting drug delivery as well as a class of chemicals, termed a drug-binding molecule of complementary structure (csDBM). The csDBM is designed to "fit" the drug by combining multiple non-covalent interactions between functional groups on the drug and opposing functional groups on the csDBM. The net result on the antibody-csDBM-drug conjugate is a drug stably bound to the csDBM so as not to dissociate during in vivo administration, but not so tightly bound to allow drug dissociation from the conjugate without significant loss of activity and retaining the drug's ability to bind to a higher affinity site on or within the target cell.

Abstract: The .alpha.-chlorohydrin content of liquid hydrolysed protein obtained by acid hydrolysis with hydrochloric acid is reduced by adjusting the pH of the liquid hydrolysed protein to a pH of from 8 to 14 and holding the liquid for a time sufficient for the .alpha.-chlorohydrin content of the liquid hydrolysed protein to be reduced.

Abstract: Methods are provided of preventing and treating chemotherapy or radiotherapy induced oral mucositis in a mammal by administering an effective dose of a growth factor, such as TGF-.alpha.. The growth factor may be used alone or in combination with other growth factors. Typically the effective dose is within the range of about 0.01-100 .mu.g/dose, administered 2-4 times daily.

Abstract: A method is provided for inhibiting the maturation of follicles in the ovary of a femal mammal comprising administering to the ovary of the mammal an effective amount of activin. This method is particularly effective in treating polycystic ovarian disease.

Abstract: The invention provides an anti-bacterial oral composition such as mouthrinse which includes a bis-biguanido hexane compound such as chlorhexidine and compounds thereof, certain non-ionic surfactants which are poly(oxyethylene)-poly(oxypropylene) block copolymers having an HLB of between 10 and 30 or an ethoxylated hydrogenated caster oil containing from about 10 to 200 moles of added ethylene oxide and sorbitol in high concentrations. The oral composition is found to increase the activity of the bis-biguanido compound from 25% to 150%.

Abstract: Basic proteins are isolated from protein mixtures which contain such basic proteins and which are obtained by enzymatic clevage of proinsulin and/or its derivatives of natural, semisynthetic or genetic engineering origin by ion exchanger chromatography on strongly acid cation exchangers.

Abstract: A stable pharmaceutically acceptable formulation containing human growth hormone, glycine, mannitol, a buffer, and optionally, a non-ionic surfactant is disclosed. The formulation contains human growth-hormone: glycine in 1:50-200 molar ratios. Also disclosed are associated means and methods for preparing and using such formulations.

Abstract: Dental cream in contact with a polyolefin resin surface of a package such as a laminate tube, a mechanical dispenser or a flexible sachet. The dental cream contains a dentally acceptable water-insoluble alkaline earth metal salt, a liquid vehicle, a gelling agent and an additive which prevents syneresis. The liquid vehicle contains water, glycerine and sorbitol. The additive which prevents syneresis due to contact between the dental cream and the polyolefin resin is a nonionic block copolymer containing moieties of polyoxyethylene and polyoxypropylene.

Abstract: A pharmaceutical composition which is a physical mixture of exifone and certain water soluble cellulose derivatives. The mixture exhibits surprisingly improved solubility and bio availability.

Abstract: Method of enhancing the survival of neuronal cells, more preferably non-mitotic neuronal cells and/or cholinergic cells in a mammal, which cells are at risk of dying, which method includes administering to the mammal an effective amount of a functional derivative of Insulin-like Growth Factor I or Insulin-like Growth Factor II.

Abstract: A polyethylene glycol derivative of the formula ##STR1## wherein R represents a lower alkyl and n represents an optional positive integer which renders the average molecular weight of the polyethylene glycol moiety about 1,000 to 12,000, a peptide modified by said polyethylene glycol derivative and a method for production thereof.The polyethylene glycol derivative (I) is capable of modifying the guanidino groups in peptides. The peptides modified by the polyethylene glycol derivative (I) are extremely stable, are considerably delayed in biological clearance (i.e. the durability is extended) and exhibit their physiological activities effectively over the long period.

Abstract: An aqueous two-phase protein partitioning system is disclosed which employs polyvinylpyrrolidone as the upper phase and maltodextrin as the lower phase and provides a low-cost system for protein partitioning. The system can also be employed with the amion derivatives of chlorotriazine dyes, which bind in a noncovalent manner with the PVP and serve as a ligand for the proteins to be separated.

Abstract: Mycobacterium bovis BCG suspensions are treated with a protease enzyme such as pronase, resulting in the production of suspensions having smaller aggregates and single cells. Such suspensions, when processed into vaccines, exhibit improved immunizing potential against cancer and would be expected to exhibit improved immunizing potential against tuberculosis.

Abstract: The invention relates to a method of treating pulmonary dysfunction in a mammal comprising administration of growth hormone to said mammal. In one embodiment wherein the pulmonary dysfunction results in ventilator dependency, the use of the method of this invention promotes the withdrawal of mechanical ventilatory support.

Abstract: A high molecular compound useful as a non-radioactive carrier, which comprises at least one unit of (1) an asialoglycoprotein acceptor-directing compound and at least one unit of (2) a chelate-forming compound chemically bonded thereto, and which may be labeled with a radioactive metallic element to give a radioactive metallic element-labeled product useful as a radioactive diagnostic or therapeutic agent for liver.